Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- GIS +2.8%, ABM +0.6%,
Other news:
- DBVT +37.5% (topline results from Phase 3 VITESSE Trial)
- HUT +20.1% (signs 15-year, 245 MW AI data center lease at River Bend campus with total contract value of $7.0 billion)
- CGEN +13.8% (reaches agreement with AstraZeneca to monetize a portion of its rilvegostomig future royalties)
- PSNL +5.8% (announces new publication applying ultrasensitive ctDNA testing to monitoring cancer immunotherapy response across solid tumors)
- QS +5.7% (successfully accomplishes annual commercial engagement goal)
- ULCC +5.6% (Spirit Airlines considering merger with ULCC amid restructuring, according to Bloomberg)
- NYXH +4.2% (launches Genio breakthrough sleep apnea therapy in the Netherlands)
- ALVO +3.8% (places $108 mln convertible bond offering)
- ZIM +2.9% (reaches deal with activist shareholders)
- RKLB +2.3% (schedules accelerated U.S. Space Force STP-S30 launch)
- PLX +2.2% (enters collaboration and option agreement with Secarna Pharmaceuticals)
- PUMP +2% (files mixed shelf offering; also files for 16.6 mln offering by selling shareholders)
- NRDS +1.9% (authorizes $50 mln increase to it share repurchase program)
- REPX +1.9% (authorizes new $100 mln share repurchase program)
- DRS +1.6% (achieves milestone with first space-based test of data transport)
- CNL +1.6% (expands ramp zone)
- FULT +1.5% (increases dividend; also new $150 mln share repurchase program)
- SLDB +1.4% (HHS officially adds Dechenne muscular dystrophy to RUSP)
- NFLX +1.4% (Warner Bros. Discovery Board of Directors unanimously recommends shareholders reject Paramount (PSKY) tender offer)
- CPNG +1.3% (discloses cybersecurity event)
- GERN +1.1% (begins restructuring plan, will implement 33% workforce reduction)
- GSK +1% (secures FDA approval for Exdensur in severe asthma)